Standigm, a company using artificial intelligence (AI) technology for drug discovery, unveiled its latest technology Standigm BEST, a service that provides better novel structures, at the 24th annual BIO-Europe international partnering conference.
The platform is an AI-driven customer-friendly service that generates better novel structures and provides lead optimization to improve customer’s desired properties such as potency, selectivity, and ADMET (Adsorption, Distribution, Metabolism, Excretion, and Toxicity).
Standigm BEST can also help with fast-follow hit identification or patent fencing strategy, the company said.
"Standigm BEST has aroused the interest of pharmaceutical companies, and the company has scheduled various one-to-one meetings with several leading pharmaceutical companies,” Standigm co-founder and CEO Kim Jin-han said. “We are expecting more deals than last year when we launched Standigm Expander.”
Standigm Expander is an AI-driven drug repurposing service launched in November 2017.
“We have gained recognition for our AI technology by providing the Expander service,” Kim said. “Through such recognition, the company is increasing employment to meet the demands from pharmaceutical companies and develop more advanced AI technology.”
<© Korea Biomedical Review, All rights reserved.>